Subtopic Deep Dive
Immunotherapy for Neuroblastoma
Research Guide
What is Immunotherapy for Neuroblastoma?
Immunotherapy for neuroblastoma uses GD2-targeted monoclonal antibodies, CAR-T cells, and cytokines to treat high-risk pediatric patients by overcoming tumor immune evasion.
Key approaches include ch14.18 anti-GD2 antibody combined with GM-CSF, interleukin-2, and isotretinoin, showing improved event-free survival in phase III trials (Yu et al., 2010, 1746 citations). CAR-T cells targeting GD2 demonstrate antitumor activity and persistence in patients (Louis et al., 2011, 1143 citations). Over 20 clinical trials since 2010 evaluate combinations with chemotherapy.
Why It Matters
Anti-GD2 immunotherapy with ch14.18, GM-CSF, and IL-2 improved 2-year event-free survival from 46% to 66% in high-risk neuroblastoma patients, establishing it as standard care (Yu et al., 2010). CAR-T therapies targeting GD2 provide long-term tumor control in relapsed cases, reducing reliance on myeloablative chemotherapy (Louis et al., 2011). These advances inform biomarker-driven trials and combination regimens for other solid tumors (Cheung and Dyer, 2013).
Key Research Challenges
CAR-T Cell Persistence
GD2 CAR-T cells show initial antitumor activity but limited long-term persistence in neuroblastoma patients due to exhaustion and tumor microenvironment factors (Louis et al., 2011). Optimizing CAR design and lymphodepletion improves outcomes but requires biomarker identification. Over 10 trials highlight variable T-cell fate post-infusion.
Tumor Hypoxia Resistance
Neuroblastoma tumors exhibit hypoxia that impairs immune cell infiltration and antibody efficacy, complicating GD2-targeted therapies (Höckel and Vaupel, 2001, 2624 citations). Hypoxia drives immune evasion mechanisms resistant to checkpoint inhibitors. Clinical trials struggle with hypoxic niche targeting in solid tumors.
Combination Regimen Toxicity
Combining anti-GD2 antibodies with cytokines like IL-2 causes severe pain and vascular leak syndrome, limiting dose intensity in pediatric patients (Yu et al., 2010). Phase I-III trials seek tolerable schedules without compromising efficacy. Biomarker selection for low-toxicity subsets remains unresolved.
Essential Papers
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Michael Höckel, Peter Vaupel · 2001 · JNCI Journal of the National Cancer Institute · 2.6K citations
Tissue hypoxia results from an inadequate supply of oxygen (O(2)) that compromises biologic functions. Evidence from experimental and clinical studies increasingly points to a fundamental role for ...
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · 2010 · New England Journal of Medicine · 1.7K citations
Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the...
Neuroblastoma
Katherine K. Matthay, John M. Maris, Gudrun Schleiermacher et al. · 2016 · Nature Reviews Disease Primers · 1.3K citations
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
Chrystal U. Louis, Barbara Savoldo, Gianpietro Dotti et al. · 2011 · Blood · 1.1K citations
Abstract We generated MHC-independent chimeric antigen receptors (CARs) directed to the GD2 antigen expressed by neuroblastoma tumor cells and treated patients with this disease. Two distinguishabl...
Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Nai‐Kong V. Cheung, Michael A. Dyer · 2013 · Nature reviews. Cancer · 800 citations
Overview and recent advances in the treatment of neuroblastoma
Sarah Burkhead Whittle, Valeria Smith, Erin Doherty et al. · 2017 · Expert Review of Anticancer Therapy · 392 citations
Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on t...
Rhabdomyosarcoma: An Overview
Ramzi Dagher, Lee J. Helman · 1999 · The Oncologist · 381 citations
Abstract Rhabdomyosarcoma (RMS) is a malignant tumor of mesenchymal origin thought to arise from cells committed to a skeletal muscle lineage. With approximately 250 cases diagnosed yearly in the U...
Reading Guide
Foundational Papers
Start with Yu et al. (2010) for ch14.18 phase III trial establishing standard care, then Louis et al. (2011) for CAR-T proof-of-concept, followed by Cheung and Dyer (2013) for genomics-immunotherapy integration.
Recent Advances
Zafar et al. (2020) reviews molecular targeting progress; Whittle et al. (2017) covers treatment advances including immunotherapy combinations.
Core Methods
GD2 monoclonal antibodies (ch14.18) with GM-CSF/IL-2 (Yu et al., 2010); first-gen GD2 CAR-T cells (Louis et al., 2011); hypoxia modulation for immune access (Höckel and Vaupel, 2001).
How PapersFlow Helps You Research Immunotherapy for Neuroblastoma
Discover & Search
Research Agent uses searchPapers('GD2 CAR-T neuroblastoma') to retrieve 50+ papers including Louis et al. (2011), then citationGraph to map influence from Yu et al. (2010) to recent trials, and findSimilarPapers for unpublished preprints via exaSearch.
Analyze & Verify
Analysis Agent applies readPaperContent on Yu et al. (2010) to extract survival data, verifyResponse with CoVe to confirm 66% event-free survival claims against raw trial stats, and runPythonAnalysis for Kaplan-Meier curve meta-analysis with GRADE scoring B-level evidence.
Synthesize & Write
Synthesis Agent detects gaps in CAR-T persistence post-Louis et al. (2011), flags contradictions between hypoxia papers (Höckel and Vaupel, 2001) and immunotherapy efficacy; Writing Agent uses latexEditText for regimen tables, latexSyncCitations for 20+ refs, and latexCompile for trial flowcharts.
Use Cases
"Extract and plot survival curves from GD2 immunotherapy trials"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on Yu 2010 data) → matplotlib survival plot with GRADE-verified stats.
"Draft LaTeX review of anti-GD2 phase III results"
Synthesis Agent → gap detection → Writing Agent → latexEditText (add Yu 2010 section) → latexSyncCitations (20 refs) → latexCompile → PDF with trial diagrams.
"Find GitHub code for neuroblastoma CAR-T simulations"
Research Agent → paperExtractUrls (Louis 2011) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on simulation code for T-cell persistence models.
Automated Workflows
Deep Research workflow scans 50+ GD2 papers via searchPapers → citationGraph → structured report with Yu et al. (2010) as hub. DeepScan applies 7-step CoVe to verify Louis et al. (2011) persistence claims against trial data. Theorizer generates hypotheses linking hypoxia (Höckel and Vaupel, 2001) to CAR-T failure mechanisms.
Frequently Asked Questions
What defines immunotherapy for neuroblastoma?
It targets GD2 with ch14.18 monoclonal antibodies, CAR-T cells, GM-CSF, and IL-2 to improve outcomes in high-risk cases (Yu et al., 2010; Louis et al., 2011).
What are main methods in GD2 immunotherapy?
ch14.18 anti-GD2 antibody plus cytokines post-transplant (Yu et al., 2010); GD2-targeted CAR-T from EBV-specific cells (Louis et al., 2011).
What are key papers?
Yu et al. (2010, NEJM, 1746 citations) on ch14.18 phase III; Louis et al. (2011, Blood, 1143 citations) on CAR-T persistence; Cheung and Dyer (2013, 800 citations) review.
What open problems exist?
CAR-T exhaustion and hypoxia resistance limit efficacy (Louis et al., 2011; Höckel and Vaupel, 2001); need biomarkers for low-toxicity combinations.
Research Neuroblastoma Research and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Immunotherapy for Neuroblastoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers